<DOC>
	<DOCNO>NCT01724320</DOCNO>
	<brief_summary>The purpose study determine recommend dose ( RD ) phase II study , Galectin-1 inhibitor OTX008 give subcutaneously patient advance solid tumor</brief_summary>
	<brief_title>A Phase I , First-in-man Study OTX008 Given Subcutaneously Single Agent Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>Overexpression galectin-1 protein well document different type cancer , associate bad prognostic enhance metastasis spread . In-vitro/in-vivo preclinical study show OTX008 inhibits galectin-1 expression . In different cancer model animal , OTX008 reduce tumor grow metastasis spread observe blood vessel architecture normalization . Thus , OTX008 appear innovate approach treat cancer clinical phase I study aims evaluate OTX008 therapy patient advance solid tumor .</detailed_description>
	<criteria>Signed informed consent prior begin protocol specific screening procedure . Patients register trial must treat follow participate center . Patients receive study treatment within 7 day registration Histologically proven malignant solid tumor Patients fail standard therapy , standard therapy deem ineffective contraindicate . Patients age &gt; 18 year . ECOG performance status ( PS ) 0 1 Off previous systemic therapy ( except LHRH agonist therapy start &gt; 2 month prior study entry could continue ) , radiation therapy , surgery least 30 day prior first study treatment administration ( 45 day bicalutamide ) . Recovery toxic effect prior treatment NCICCTC grade &lt; 1 , except alopecia Adequate bone marrow function include : Neutrophils &gt; = 1.5 x 10E9 /L ; platelet &gt; = 100 x 10E9 /L , Hb &gt; 8g/dL without transfusion . Creatinine clearance &gt; = 60 mL/min ( Cockroft &amp; Gault formula , MDRD formula patient age &gt; 65 year ) . Adequate LFTs : Total bilirubin &lt; 1 x institutional upper normal limit ( UNL ) ; ALAT/ASAT &gt; = 3 x UNL ( &gt; = 5 x UNL case liver metastasis ) . Serum albumin &gt; 28g/L . Availability last tumor image within 6 month prior baseline tumor image Availability archive pathology specimen ( paraffinembedded block ) tumor History prior malignancy previously treat curative intent 5 year ago without relapse ( tumor ) basal cell skin cancer , situ cervical cancer , superficial bladder cancer , high grade intestinal polyp treat adequately , regardless diseasefree interval . Pregnant lactate woman woman childbearing potential use adequate contraception . Male patient use adequate contraception . Tumor sit necessitate immediate intervention ( supportive care , surgery radiation therapy ) symptomatic brain leptomeningeal tumor , spinal cord compression , compressive tumor mass , painful bone metastasis , bone fracture , etcâ€¦ Other serious illness medical condition , , investigator 's opinion could jeopardize patient 's safety hamper understand study patient , patient 's compliance study treatment , interpretation study result . These condition include ( restrict ) : 1 . Congestive heart failure angina pectoris medically control . Previous history myocardial infarction within 1 year study entry , uncontrolled hypertension arrhythmia . 2 . Existence significant neurologic psychiatric disorder impair ability obtain consent . 3 . Active infection . Concurrent treatment experimental therapy participation another clinical trial within 30 day prior first study treatment administration . Concurrent treatment anticancer therapy ( except LHRH agonist therapy initiate &gt; 2 month prior study entry ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>solid tumor</keyword>
	<keyword>first-in-man</keyword>
	<keyword>phase I</keyword>
	<keyword>cancer</keyword>
	<keyword>galectin</keyword>
</DOC>